News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,554 Results
Type
Article (14061)
Company Profile (284)
Press Release (249209)
Section
Business (79447)
Career Advice (152)
Deals (13215)
Drug Delivery (34)
Drug Development (50398)
Employer Resources (31)
FDA (5701)
Job Trends (5121)
News (144293)
Policy (10024)
Tag
Academia (902)
Alliances (21599)
Alzheimer's disease (785)
Antibody-drug conjugate (ADC) (70)
Approvals (5685)
Artificial intelligence (90)
Bankruptcy (99)
Best Places to Work (4550)
Biotechnology (233)
Breast cancer (123)
Cancer (1039)
Cardiovascular disease (84)
Career advice (132)
CAR-T (86)
Cell therapy (248)
Clinical research (40431)
Collaboration (398)
Compensation (155)
COVID-19 (1021)
C-suite (104)
Cystic fibrosis (72)
Data (1073)
Diabetes (96)
Diagnostics (1236)
Earnings (29089)
Events (47504)
Executive appointments (326)
FDA (6143)
Funding (378)
Gene editing (71)
Gene therapy (186)
GLP-1 (333)
Government (1069)
Healthcare (6562)
Infectious disease (1062)
Inflammatory bowel disease (100)
IPO (7231)
Job creations (860)
Job search strategy (127)
Layoffs (193)
Legal (1379)
Lung cancer (154)
Manufacturing (93)
Medical device (2566)
Medtech (2567)
Mergers & acquisitions (6186)
Metabolic disorders (296)
Neuroscience (1079)
NextGen: Class of 2025 (2013)
Non-profit (851)
Northern California (1240)
Obesity (161)
Opinion (93)
Parkinson's disease (85)
Patents (72)
People (25279)
Phase I (14270)
Phase II (18802)
Phase III (11890)
Pipeline (458)
Postmarket research (852)
Preclinical (5987)
Radiopharmaceuticals (208)
Rare diseases (230)
Real estate (1411)
Regulatory (8376)
Research institute (934)
Series A (74)
Southern California (1114)
Startups (1968)
United States (9825)
Vaccines (177)
Weight loss (94)
Date
Today (109)
Last 7 days (351)
Last 30 days (1550)
Last 365 days (20459)
2025 (1550)
2024 (20559)
2023 (22435)
2022 (26835)
2021 (27810)
2020 (23367)
2019 (16226)
2018 (11743)
2017 (13747)
2016 (11840)
2015 (14369)
2014 (10404)
2013 (7506)
2012 (7558)
2011 (7636)
2010 (7434)
Location
Africa (146)
Asia (17039)
Australia (2882)
California (2833)
Canada (890)
China (254)
Colorado (105)
Connecticut (118)
Delaware (65)
Europe (36668)
Florida (319)
Georgia (84)
Illinois (177)
Indiana (68)
Maryland (370)
Massachusetts (2249)
Minnesota (113)
New Jersey (704)
New York (778)
North Carolina (449)
Northern California (1240)
Ohio (91)
Pennsylvania (535)
South America (207)
Southern California (1114)
Texas (316)
Washington State (271)
263,554 Results for "galectin therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
MASH
Phase III MASH Miss Sends Galectin Stock Tumbling
Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint for its Phase IIb/III trial for patients with a type of liver cirrhosis.
December 20, 2024
·
1 min read
·
Kate Goodwin
Press Releases
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
January 10, 2025
·
2 min read
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
Galectin Therapeutics Inc. announced today the Company will be attending and presenting at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference.
May 13, 2024
·
2 min read
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
Galectin Therapeutics Inc. today announced that it will attend the EASL 2024 meeting and deliver a scientific presentation. The meeting will be held June 5-8, 2024, in Milan, Italy.
June 4, 2024
·
5 min read
Business
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023.
March 29, 2024
·
9 min read
Business
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
Galectin Therapeutics, Inc. today reported financial results and provided a business update for the quarter ended March 31, 2024.
May 15, 2024
·
8 min read
Press Releases
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH
December 20, 2024
·
9 min read
Press Releases
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
September 30, 2024
·
1 min read
Press Releases
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
November 14, 2024
·
8 min read
Press Releases
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
November 18, 2024
·
4 min read
1 of 26,356
Next
